Management of Relapses in RRMS After First Ocrelizumab Dose
Treat relapses occurring after the first ocrelizumab infusion with high-dose corticosteroids (typically methylprednisolone 1000 mg IV daily for 3-5 days or equivalent oral prednisone), while continuing ocrelizumab as scheduled unless the relapse indicates treatment failure.
Distinguishing True Relapses from Pseudo-Relapses
Before initiating treatment, you must differentiate between:
- True relapse: New or worsening neurological symptoms lasting >24 hours, occurring at least 30 days after the previous relapse, without fever or infection 1
- Pseudo-relapse: Symptom worsening triggered by fever, infection, heat exposure, or metabolic disturbances 1
- Symptom fluctuation: Day-to-day variability in pre-existing symptoms without new objective findings
Only true relapses warrant corticosteroid therapy. Pseudo-relapses resolve by treating the underlying trigger (infection, fever reduction, cooling).
Corticosteroid Treatment Protocol
When treating a confirmed relapse:
- Methylprednisolone 1000 mg IV daily for 3-5 days (most common regimen)
- Alternative: High-dose oral prednisone (1250 mg daily for 3-5 days) if IV access is problematic
- No taper required for short courses 1
- Corticosteroids accelerate recovery but don't affect long-term disability outcomes
Continuing Ocrelizumab Therapy
Do not interrupt the ocrelizumab dosing schedule based on a single relapse 2. The clinical trials establishing ocrelizumab's efficacy showed:
- Annualized relapse rate of 0.16 with ocrelizumab vs 0.29 with interferon beta-1a 2
- 47% relative reduction in confirmed disability progression 2
- Relapses can still occur, particularly in the first 6 months as B-cell depletion takes effect
Continue ocrelizumab 600 mg IV every 24 weeks as scheduled. The second dose (first full 600 mg infusion) should be given 24 weeks after the initial split dose, regardless of relapse occurrence.
When to Consider Treatment Failure
Reassess the treatment strategy if:
- Multiple relapses (≥2) occur within the first 12 months despite adequate B-cell depletion
- Severe relapse with incomplete recovery occurs
- MRI shows significant new activity: Multiple new T2 lesions or gadolinium-enhancing lesions at 6-12 month follow-up 2
- Confirmed disability progression despite treatment
In these scenarios, verify adequate B-cell depletion (CD19+ B-cells should be <10 cells/μL) before concluding treatment failure.
Monitoring After Relapse
Following relapse treatment:
- Clinical reassessment at 4-6 weeks to document recovery
- MRI at 6 months from ocrelizumab initiation (or sooner if severe relapse) to establish new baseline 3
- Check CD19+ B-cell count if questioning treatment adequacy
- Document EDSS score to track any residual disability
Special Considerations
Infection screening: Before attributing symptoms to MS relapse, exclude:
- Urinary tract infection (most common MS relapse mimic)
- Respiratory infections
- Other systemic infections that can cause pseudo-relapses
Timing of relapse: Relapses occurring within 3 months of ocrelizumab initiation may represent disease activity from before B-cell depletion was complete. This doesn't necessarily indicate treatment failure 4.
Severe presentations: For relapses with severe disability (e.g., transverse myelitis, optic neuritis with severe vision loss), consider plasma exchange (5-7 exchanges) if no improvement occurs after 5-7 days of high-dose corticosteroids 1.